OBJECTIVE: A recent randomized clinical trial demonstrated home-based treatment of WHO-defined severe pneumonia with oral amoxicillin was equivalent to hospital-based therapy and parenteral antibiotics. We aimed to determine whether this finding is generalizable across four countries. METHODS: Multicentre observational study in Bangladesh, Egypt, Ghana and Vietnam between November 2005 and May 2008. Children aged 3-59 months with WHO-defined severe pneumonia were enrolled at participating health centres and managed at home with oral amoxicillin (80-90 mg/kg per day) for 5 days. Children were followed up at home on days 1, 2, 3 and 6 and at a facility on day 14 to look for cumulative treatment failure through day 6 and relapse between days 6 and 14. RESULTS: Of 6582 children screened, 873 were included, of whom 823 had an outcome ascertained. There was substantial variation in presenting characteristics by site. Bangladesh and Ghana had fever (97%) as a more common symptom than Egypt (74%) and Vietnam (66%), while in Vietnam, audible wheeze was more common (49%) than at other sites (range 2-16%). Treatment failure by day 6 was 9.2% (95% CI: 7.3-11.2%) across all sites, varying from 6.4% (95% CI: 3.1-9.8%) in Ghana to 13.2% (95% CI: 8.4-18.0%) in Vietnam; 2.7% (95% CI: 1.5-3.9%) of the 733 children well on day 6 relapsed by day 14. The most common causes of treatment failure were persistence of lower chest wall indrawing (LCI) at day 6 (3.8%; 95% CI: 2.6-5.2%), abnormally sleepy or difficult to wake (1.3%; 95% CI: 0.7-2.3%) and central cyanosis (1.3%; 95% CI: 0.7-2.3%). All children survived and only one adverse drug reaction occurred. Treatment failure was more frequent in young infants and those presenting with rapid respiratory rates. CONCLUSIONS: Clinical treatment failure and adverse event rates among children with severe pneumonia treated at home with oral amoxicillin did not substantially differ across geographic areas. Thus, home-based therapy of severe pneumonia can be applied to a wide variety of settings.
OBJECTIVE: A recent randomized clinical trial demonstrated home-based treatment of WHO-defined severe pneumonia with oral amoxicillin was equivalent to hospital-based therapy and parenteral antibiotics. We aimed to determine whether this finding is generalizable across four countries. METHODS: Multicentre observational study in Bangladesh, Egypt, Ghana and Vietnam between November 2005 and May 2008. Children aged 3-59 months with WHO-defined severe pneumonia were enrolled at participating health centres and managed at home with oral amoxicillin (80-90 mg/kg per day) for 5 days. Children were followed up at home on days 1, 2, 3 and 6 and at a facility on day 14 to look for cumulative treatment failure through day 6 and relapse between days 6 and 14. RESULTS: Of 6582 children screened, 873 were included, of whom 823 had an outcome ascertained. There was substantial variation in presenting characteristics by site. Bangladesh and Ghana had fever (97%) as a more common symptom than Egypt (74%) and Vietnam (66%), while in Vietnam, audible wheeze was more common (49%) than at other sites (range 2-16%). Treatment failure by day 6 was 9.2% (95% CI: 7.3-11.2%) across all sites, varying from 6.4% (95% CI: 3.1-9.8%) in Ghana to 13.2% (95% CI: 8.4-18.0%) in Vietnam; 2.7% (95% CI: 1.5-3.9%) of the 733 children well on day 6 relapsed by day 14. The most common causes of treatment failure were persistence of lower chest wall indrawing (LCI) at day 6 (3.8%; 95% CI: 2.6-5.2%), abnormally sleepy or difficult to wake (1.3%; 95% CI: 0.7-2.3%) and central cyanosis (1.3%; 95% CI: 0.7-2.3%). All children survived and only one adverse drug reaction occurred. Treatment failure was more frequent in young infants and those presenting with rapid respiratory rates. CONCLUSIONS: Clinical treatment failure and adverse event rates among children with severe pneumonia treated at home with oral amoxicillin did not substantially differ across geographic areas. Thus, home-based therapy of severe pneumonia can be applied to a wide variety of settings.
Authors: J Pépin; A M Demers; F Mberyo-Yaah; S Jaffar; C Blais; P Somsé; G Bobossi; P Morency Journal: Trans R Soc Trop Med Hyg Date: 2001 Jul-Aug Impact factor: 2.184
Authors: Maria-Regina A Cardoso; Cristiana M Nascimento-Carvalho; Fernando Ferrero; Fátima M Alves; Simon N Cousens Journal: Arch Dis Child Date: 2010-09-23 Impact factor: 3.791
Authors: Tabish Hazir; LeAnne M Fox; Yasir Bin Nisar; Matthew P Fox; Yusra Pervaiz Ashraf; William B MacLeod; Afroze Ramzan; Sajid Maqbool; Tahir Masood; Waqar Hussain; Asifa Murtaza; Nadeem Khawar; Parveen Tariq; Rai Asghar; Jonathon L Simon; Donald M Thea; Shamim A Qazi Journal: Lancet Date: 2008-01-05 Impact factor: 79.321
Authors: T Juvén; J Mertsola; M Waris; M Leinonen; O Meurman; M Roivainen; J Eskola; P Saikku; O Ruuskanen Journal: Pediatr Infect Dis J Date: 2000-04 Impact factor: 2.129
Authors: Robert E Black; Simon Cousens; Hope L Johnson; Joy E Lawn; Igor Rudan; Diego G Bassani; Prabhat Jha; Harry Campbell; Christa Fischer Walker; Richard Cibulskis; Thomas Eisele; Li Liu; Colin Mathers Journal: Lancet Date: 2010-05-11 Impact factor: 79.321
Authors: Jonathan C Craig; Gabrielle J Williams; Mike Jones; Miriam Codarini; Petra Macaskill; Andrew Hayen; Les Irwig; Dominic A Fitzgerald; David Isaacs; Mary McCaskill Journal: BMJ Date: 2010-04-20
Authors: Shams E Arifeen; Samir K Saha; Sayedur Rahman; Kazi Mizanur Rahman; Syed Moshfiqur Rahman; Sanwarul Bari; Aliya Naheed; Ishtiaq Mannan; M Habibur R Seraji; Nawshad U Ahmed; M Shameem Hassan; Nazmul Huda; Ashraf Uddin Siddik; Iftekhar Quasem; Maksuda Islam; Kaniz Fatima; Hassan Al-Emran; W Abdullah Brooks; Abdullah H Baqui; Robert F Breiman; David Sack; Stephen P Luby Journal: Clin Infect Dis Date: 2009-03-01 Impact factor: 9.079
Authors: Samir K Saha; Aliya Naheed; Shams El Arifeen; Maksuda Islam; Hassan Al-Emran; Ruhul Amin; Kaniz Fatima; W Abdullah Brooks; Robert F Breiman; David A Sack; Stephen P Luby Journal: Clin Infect Dis Date: 2009-03-01 Impact factor: 9.079
Authors: Abdul Bari; Salim Sadruddin; Attaullah Khan; Ibad ul Haque Khan; Amanullah Khan; Iqbal A Lehri; William B Macleod; Matthew P Fox; Donald M Thea; Shamim A Qazi Journal: Lancet Date: 2011-11-10 Impact factor: 79.321
Authors: Clare Webb; Mwanajuma Ngama; Anthony Ngatia; Mohammed Shebbe; Susan Morpeth; Salim Mwarumba; Ann Bett; D James Nokes; Anna C Seale; Sidi Kazungu; Patrick Munywoki; Laura L Hammitt; J Anthony G Scott; James A Berkley Journal: Pediatr Infect Dis J Date: 2012-09 Impact factor: 2.129
Authors: Matthew P Fox; Donald M Thea; Salim Sadruddin; Abdul Bari; Rachael Bonawitz; Tabish Hazir; Yasir Bin Nisar; Shamim A Qazi Journal: Clin Infect Dis Date: 2012-12-21 Impact factor: 9.079
Authors: Arthur Bagonza; Freddy Eric Kitutu; Stefan Peterson; Andreas Mårtensson; Milton Mutto; Phyllis Awor; David Mukanga; Henry Wamani Journal: Health Sci Rep Date: 2021-05-07
Authors: Eric D McCollum; Carina King; Robert Hollowell; Janet Zhou; Tim Colbourn; Bejoy Nambiar; David Mukanga; Deborah C Hay Burgess Journal: BMC Pediatr Date: 2015-07-09 Impact factor: 2.125